Latest News
Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics
Takeda expands de novo protein research by signing second deal with AI specialist Nabla Bio
AI Conjures Up Potential New Antibody Drugs in a Matter of Months
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership
AI-based protein discovery start-up strikes a second deal with Takeda
Designed by AI: the future of antibody drugs
Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox
Test-Time Scaling Improves Speed and Success of AI-Based Antibody Design
De novo design of hundreds of functional GPCR-targeting antibodies enabled by scaling test-time compute
Test-Time Scaling Unlocks a Leap Forward in De Novo Antibody Design
Two biotechs say they’re using AI to conjure drugs from scratch. Their documents suggest otherwise
Better antibodies by engineering targets, not engineering antibodies (Nabla Bio)
With all eyes on AI-protein design, Nabla says it can model therapeutic antibodies